Previous 10 | Next 10 |
10x Genomics ' (NASDAQ: TXG) technology has been used by researchers to investigate multiple diseases over the last few years. In this video recorded on March 11, 2021 , Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Serge Saxonov about tw...
Multiple sclerosis (MS) affects more than 1 million people in the U.S. But advances in treating the disease continue to be made, especially with new tools for genomic research into the underlying issues that lead to MS. In this video recorded on March 11, 2021 , Jason Hall, multime...
10x Genomics (NASDAQ: TXG) has seen its market cap nearly quadruple since going public in 2019. But the company is still only in its early innings of growth. In this video recorded on March 11, 2021 , Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics CEO an...
Innovators can often spot other innovators early on. 10x Genomics (NASDAQ: TXG) certainly stands out as an innovator in the genomics research world. In this video recorded on March 11 , Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics CEO and co-founder Se...
Medical advances over the last 150 years have led to humans living much longer lives than in the past. But the pace of medical discovery now is breathtaking, particularly with the progress in genomic research. In this video, recorded on March 11 , Jason Hall, the host and multimedia spe...
Some have referred to the 21st century as the "century of biology." That's probably not an overstatement. In this video recorded on March 11, 2021 , Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics (NASDAQ: TXG) CEO and co-founder Serge Saxonov about his t...
10x Genomics (NASDAQ: TXG) has gobbled up several smaller companies over the last year. These deals have extended the company's offerings and expanded its addressable market in some cases. In this video recorded on March 11, 2021 , Motley Fool contributor Keith Speights tal...
10x Genomics (NASDAQ: TXG) generated sales of nearly $300 million in 2020. The genomics company's market cap now stands at close to $20 billion. But 10x is just getting started. In this video recorded on March 11, 2021 , Motley Fool contributor Keith Speights talks with 10x...
Some areas of the U.S. and across the world are experiencing increased cases of COVID-19. However, there's also plenty of good news. In this video recorded on March 11, 2021 , Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics (NASDAQ: TXG) CEO and co-founde...
10x Genomics (NASDAQ: TXG) has come a long way since opening its doors in 2012. The genomics company now has a market cap of close to $20 billion. In this video recorded on March 11, 2021 , Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Se...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...